Ixazomib-dexamethasone (Ixa-Dex) vs physician's choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial Meeting Abstract
| Authors: | Kastritis, E.; Dispenzieri, A.; Wechalekar, A. D.; Schonland, S. O.; Kim, K.; Sanchorawala, V.; Landau, H. J.; Kwok, F.; Suzuki, K.; Comenzo, R.; Palladini, G.; Berg, D.; Liu, G. H.; Kumar, A.; Faller, D. V.; Merlini, G. |
| Abstract Title: | Ixazomib-dexamethasone (Ixa-Dex) vs physician's choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Start Page: | 446s |
| Language: | English |
| ACCESSION: | WOS:000560368303331 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.8546 |
| Notes: | Meeting Abstract: 8546 -- Source: Wos |
